Disfagia, QoL e atteggiamenti nei confronti del PEG nei pazienti affetti da SLA (ALSDPEG)
Disfagia, qualità della vita e atteggiamenti nei confronti della gastrostomia endoscopica percutanea nei pazienti con sclerosi laterale amiotrofica
In Amyotrophic Lateral Sclerosis, dysphagia has a high incidence. With deterioration of swallowing function, percutaneous endoscopic gastrostomy (PEG) tube is recommended to ensure sufficient and safe oral intake. Dysphagia and PEG placement alter quality of life (QoL). However, QoL and attitudes toward PEG remain largely unexplored. The purpose of this study is to monitor the swallowing function in relationship to QoL and attitudes toward PEG tube insertion and feeding.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The purpose of this study is to monitor the deterioration of swallowing function in ALS patient population, and to explore its impact on QoL and attitudes toward PEG tube insertion and feeding in the course of the disease. It will take maximum of 60 minutes to fully evaluate the swallowing function and complete the questionnaires. The evaluation procedure will be repeated every 3 months until PEG tube insertion, which will allow us to closely monitor the swallowing function in a relation to attitudes toward PEG and QoL. The data obtained from this study should contribute significantly to the knowledge of QoL in ALS patients with dysphagia, and it will allow for a comparison of QoL in ALS patients with and without PEG tube. This study will also expand the understanding of attitudes in ALS patients and their relatives toward PEG, and the impact of those attitudes on the decision-making process.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Metka Moharić, MD, PhD
- Numero di telefono: +386 1 4758441
- Email: metka.moharic@ir-rs.si
Luoghi di studio
-
-
-
Ljubljana, Slovenia, 1000
- Reclutamento
- University Medical Centre Ljubljana
-
Contatto:
- Blaž Koritnik, MD, PhD
- Numero di telefono: +386 1 5221501
- Email: blaz.koritnik@kclj.si
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
The study will include adult ALS patients able to visit the study site for in-person procedures every 3 months, and their close relatives.
Descrizione
Inclusion Criteria for patients:
- 18 years of age or older
- diagnosis of ALS
- follow-up at University Medical Centre Ljubljana, Division of Neurophysiology, every 3 months
- be able to visit the study site for in-person procedures every 3 months
Inclusion Criteria for relatives:
- at least 18 years of age
Exclusion Criteria for patients:
- co-existing illness or disorder that could influence the swallowing function independently of the ALS diagnosis
- clinically significant cognitive deterioration or dementia at enrollment, as determined by the ALS study neurologist
Exclusion criteria for relatives:
- signs of probable cognitive deterioration or dementia at enrollment
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
ALS Patients
Patients with confirmed amyotrophic lateral sclerosis. |
IOPI measures the peak pressure of the tongue strength and endurance using a disposable bulb placed on a hard palate behind the front teeth or at the base of the tongue. The participants will be asked to press the bulb with their tongue with maximum pressure, three times. To measure the endurance, the participants will be asked to hold the pressure for as long as they can. MASA is a standard clinical swallowing assessment protocol including general patient examination, on-the-outside visible signs of oral preparatory and transportation phase and pharyngeal phase of swallowing function. The subjects will ingest up to 10 boluses ranging in thickness and volume (from thin to extremely-thick and a cookie). Respiratory function measurements will include forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP), all expressed in percentage of predicted values. Conventional methods of testing will be applied. |
|
Relatives
Close relatives of the patients included in the study. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Penetration-Aspiration Scale (PAS) change
Lasso di tempo: Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
PAS is an 8-point scale used to determine swallowing safety. Levels 1 and 2 are considered safe, levels >3 indicate penetration or aspiration and are considered unsafe. |
Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
|
Yale Residue Severity Rating Scale (YRSRS) change
Lasso di tempo: Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
YRSRS is a validated measure of swallowing efficiency using an image-based assessment to determine post-swallow pharyngeal residue: location and severity. It is assessed using a 5-point ordinal scale (from 1=0 % residue to 5=50 % residue). |
Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
|
Iowa Oral Performance Instrument (IOPI) change
Lasso di tempo: Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
IOPI is a device which measures tongue strength (in kilopascals; kPa) and endurance (in seconds) while the participant presses the bulb with the front or the base of their tongue to the hard palate. |
Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
|
Mann Assessment of Swallowing Ability (MASA) change
Lasso di tempo: Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
MASA is a standard clinical swallowing assessment protocol administered by the speech-language therapist. Total score ranges from 38-200. Lower score indicates higher impairment. |
Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
|
Eating Assessment Tool 10 (EAT-10) change
Lasso di tempo: Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
EAT-10 is a validated self-administered dysphagia severity symptom survey including 10 items and a five-point scale (0=no problem to 4=sever problem). Higher total score indicates higher impairment. |
Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
|
Swallowing Quality of Life Questionnaire (SWAL-QoL) change
Lasso di tempo: At baseline and every 3 months until PEG insertion, 3 and 6 months after PEG insertion
|
SWAL-QoL is a 44-item standardised psychometric scale that measures swallowing-related QoL across 10 domains. Scores for each individual domain and a total SWAL-QoL score are calculated. Total score ranges from 0-100 (100 indicating the most favourable state). |
At baseline and every 3 months until PEG insertion, 3 and 6 months after PEG insertion
|
|
Questionnaire on Attitudes Toward PEG Tube Feeding and Insertion Procedure change
Lasso di tempo: Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
The questionnaire comprises 10 questions. The participants specify their level of agreement on a five-point Likert-type scale (1=strongly disagree, 5= strongly agree). |
Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
ALS Functional Rating Scale-Revised (ALSFRS-R) change
Lasso di tempo: Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
ALSFRS-R is a 12-tem ALS-specific assessment of global functioning using a five-point scale (0=not able, 4= normal ability), with 48 points representing normal function. |
Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
|
Functional Oral Intake Scale (FOIS) change
Lasso di tempo: Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
FOIS is a validated 7-point scale demonstrating an individual's ability of daily oral food intake (1=no oral intake, 7=total oral intake with no restrictions). |
Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
|
Dysphagia Outcome and Severity Scale (DOSS) change
Lasso di tempo: Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
DOSS is a 7-point scale that rates the functional severity of dysphagia based on objective assessment and provides information on diet recommendations, independence level and type of nutrition necessary (level 7=normal swallowing function, level 1=severe dysphagia). |
Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
|
BMI change
Lasso di tempo: Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
Body mass index (in kg/m^2) |
Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
|
Forced Vital Capacity (FVC) change
Lasso di tempo: Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
Standard clinical respiratory assessment of FVC (in %) |
Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
|
Peak Cough Flow (PCF) change
Lasso di tempo: Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
Standard clinical respiratory assessment of PCF (in L/min) |
Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
|
Maximal Inspiratory Pressure (MIP) change
Lasso di tempo: Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
Standard clinical respiratory assessment of MIP (in cmH2) |
Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
|
Maximal Expiratory Pressure (MEP) change
Lasso di tempo: Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
Standard clinical respiratory assessment of MEP (in cmH2) |
Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months)
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Blaž Koritnik, MD, PhD, University Medical Centre Ljubljana
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Malattie neuromuscolari
- Malattie metaboliche
- Malattie Neurodegenerative
- Malattie del midollo spinale
- TDP-43 Proteinopatie
- Carenze di proteostasi
- Malattia del motoneurone
- Malattie nutrizionali e metaboliche
- Sclerosi laterale amiotrofica
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- URIS202201
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .